|
AU2002231736A1
(en)
|
2000-12-22 |
2002-07-08 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
|
EP1228766A1
(en)
*
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 phosphorylation by HER3 induces tumor invasion
|
|
US8505468B2
(en)
*
|
2002-11-19 |
2013-08-13 |
Sharp Kabushiki Kaisha |
Substrate accommodating tray
|
|
EP1868647A4
(en)
*
|
2005-03-24 |
2009-04-01 |
Millennium Pharm Inc |
OV064 BINDING ANTIBODIES AND METHOD FOR THEIR USE
|
|
US8759490B2
(en)
|
2005-03-24 |
2014-06-24 |
Millennium Pharamaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
|
CN101277974A
(zh)
|
2005-09-30 |
2008-10-01 |
阿伯特有限及两合公司 |
排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
|
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
AU2015201263B2
(en)
*
|
2005-12-30 |
2017-01-12 |
Amgen Inc. |
Material and methods for treating or preventing her-3 associated diseases
|
|
WO2008064884A1
(en)
|
2006-11-28 |
2008-06-05 |
U3 Pharma Gmbh |
Activated her3 as a marker for predicting therapeutic efficacy
|
|
NZ579644A
(en)
|
2007-02-16 |
2012-05-25 |
Merrimack Pharmaceuticals Inc |
Antibodies against erbb3 and uses thereof
|
|
AU2008230795B2
(en)
|
2007-03-27 |
2014-05-29 |
Bioassets, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
EP2282769A4
(en)
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
|
BRPI0911451A2
(pt)
*
|
2008-05-25 |
2019-09-24 |
Wyeth Llc |
biomarcadores para eficácia medicamentosa de egfr/her/erb
|
|
KR20110016959A
(ko)
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
EP2138511A1
(en)
*
|
2008-06-27 |
2009-12-30 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
HER3 as a determinant for the prognosis of melanoma
|
|
US8822645B2
(en)
|
2008-07-08 |
2014-09-02 |
Abbvie Inc. |
Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
|
|
AU2013202393B2
(en)
*
|
2008-07-16 |
2015-01-22 |
Institute For Research In Biomedicine |
Human cytomegalovirus nuetralizing antibodies and use thereof
|
|
KR20110044905A
(ko)
|
2008-08-15 |
2011-05-02 |
메리맥 파마슈티컬즈, 인크. |
치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
|
|
JP2012507299A
(ja)
*
|
2008-10-31 |
2012-03-29 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Ｌｉｇｈｔ標的分子およびその使用
|
|
WO2010085845A1
(en)
*
|
2009-01-28 |
2010-08-05 |
The University Of Queensland |
Cancer therapy and/or diagnosis
|
|
CA2753119A1
(en)
*
|
2009-02-24 |
2010-09-02 |
F. Hoffmann-La Roche Ag |
Use of s-erbb-3 as a marker for cancer
|
|
KR20150036824A
(ko)
|
2009-03-20 |
2015-04-07 |
제넨테크, 인크. |
이중특이적 항-ｈｅｒ 항체
|
|
CN102378768A
(zh)
|
2009-04-07 |
2012-03-14 |
罗氏格黎卡特股份公司 |
双特异性抗-ErbB-3/抗-c-Met抗体
|
|
JP2012525432A
(ja)
*
|
2009-04-29 |
2012-10-22 |
トレリス バイオサイエンス リミテッド ライアビリティー カンパニー |
ヘレグリン共役型ｈｅｒ３と免疫反応性の改善された抗体
|
|
US20120128671A1
(en)
|
2009-05-13 |
2012-05-24 |
Lawrence Horowitz |
Neutralizing molecules to influenza viruses
|
|
WO2011004899A1
(en)
*
|
2009-07-06 |
2011-01-13 |
Takeda Pharmaceutical Company Limited |
Cancerous disease modifying antibodies
|
|
MX2012002651A
(es)
|
2009-09-01 |
2012-05-22 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
CA2775573A1
(en)
*
|
2009-10-09 |
2011-04-14 |
Merck Sharp & Dohme Corp. |
Generation, characterization and uses thereof of anti-her 3 antibodies
|
|
AR078651A1
(es)
|
2009-10-15 |
2011-11-23 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
MY173390A
(en)
*
|
2009-10-23 |
2020-01-22 |
Takeda Pharmaceuticals Co |
Anti-gcc antibody molecules and related compositions and methods
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US9139825B2
(en)
|
2009-10-30 |
2015-09-22 |
Novartis Ag |
Universal fibronectin type III bottom-side binding domain libraries
|
|
KR101806323B1
(ko)
*
|
2009-11-13 |
2017-12-07 |
다이이치 산쿄 유럽 게엠베하 |
Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
|
|
PH12012501070A1
(en)
|
2009-12-08 |
2017-08-23 |
Abbott Gmbh & Co Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
|
PH12012501157A1
(en)
*
|
2009-12-22 |
2012-10-29 |
Roche Glycart Ag |
Anti-her3 antibodies and uses thereof
|
|
CA2791652C
(en)
|
2010-03-02 |
2018-06-12 |
Kyowa Kirin Co., Ltd. |
Modified antibody composition
|
|
US8895001B2
(en)
|
2010-03-11 |
2014-11-25 |
Merrimack Pharmaceuticals, Inc. |
Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
|
|
KR101764453B1
(ko)
*
|
2010-04-09 |
2017-08-02 |
아베오 파마슈티컬즈, 인크. |
항-erbb3 항체
|
|
US9932403B2
(en)
|
2010-05-20 |
2018-04-03 |
Ablynx Nv |
Biological materials related to HER3
|
|
JP2013539453A
(ja)
|
2010-07-09 |
2013-10-24 |
エクセリクシス， インク． |
癌の治療のためのキナーゼ阻害物質の組み合わせ
|
|
AU2011283646B2
(en)
|
2010-07-30 |
2015-07-09 |
Novartis Ag |
Fibronectin cradle molecules and libraries thereof
|
|
KR20130100118A
(ko)
|
2010-08-03 |
2013-09-09 |
아비에 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
WO2012019024A2
(en)
*
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
|
AU2011286407A1
(en)
*
|
2010-08-06 |
2013-02-21 |
Amgen |
Use of HER3 binding agents in prostate treatment
|
|
ME02637B
(me)
*
|
2010-08-20 |
2017-06-20 |
Novartis Ag |
Antitela za receptor 3 faktora rasta epiderma (her3)
|
|
US9046513B2
(en)
|
2010-08-26 |
2015-06-02 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
TW201302793A
(zh)
*
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
IT1402149B1
(it)
*
|
2010-10-04 |
2013-08-28 |
Ist Fisioterap Ospitalroma |
Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
|
|
CA2813796C
(en)
*
|
2010-10-18 |
2019-01-15 |
Mediapharma S.R.L. |
Erbb3 binding antibody
|
|
US9155802B2
(en)
|
2010-11-01 |
2015-10-13 |
Symphogen A/S |
Pan-HER antibody composition
|
|
WO2012059857A2
(en)
|
2010-11-01 |
2012-05-10 |
Symphogen A/S |
Pan-her antibody composition
|
|
ITRM20100577A1
(it)
*
|
2010-11-02 |
2012-05-03 |
Takis Srl |
Immunoterapia contro il recettore erbb-3
|
|
WO2012081628A1
(ja)
|
2010-12-15 |
2012-06-21 |
大学共同利用機関法人情報・システム研究機構 |
タンパク質の生産方法
|
|
CA2823337C
(en)
*
|
2010-12-29 |
2019-09-10 |
Expression Pathology, Inc. |
Her3 protein srm/mrm assay
|
|
US20140134170A1
(en)
|
2011-03-11 |
2014-05-15 |
Merrimack Pharmaceuticals, Inc. |
Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
|
|
EP2815765A1
(en)
|
2011-03-15 |
2014-12-24 |
Merrimack Pharmaceuticals, Inc. |
Overcoming resistance to ERBB pathway inhibitors
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
NO2707391T3
(enExample)
*
|
2011-05-13 |
2018-04-07 |
|
|
|
US9127065B2
(en)
|
2011-05-19 |
2015-09-08 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Anti-human HER3 antibodies and uses thereof
|
|
WO2012176779A1
(ja)
|
2011-06-20 |
2012-12-27 |
協和発酵キリン株式会社 |
抗ｅｒｂＢ３抗体
|
|
CA2842860A1
(en)
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies, Llc |
Sur-binding proteins
|
|
WO2013033008A2
(en)
|
2011-08-26 |
2013-03-07 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
US9273143B2
(en)
|
2011-09-30 |
2016-03-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
|
|
WO2013048883A2
(en)
|
2011-09-30 |
2013-04-04 |
Regeneron Pharmaceuticals, Inc. |
Anti-erbb3 antibodies and uses thereof
|
|
EP2764364B1
(en)
|
2011-10-06 |
2021-08-18 |
Aveo Pharmaceuticals, Inc. |
Predicting tumor response to anti-erbb3 antibodies
|
|
US9522951B2
(en)
|
2011-10-31 |
2016-12-20 |
Bristol-Myers Squibb Company |
Fibronectin binding domains with reduced immunogenicity
|
|
WO2013071058A1
(en)
*
|
2011-11-09 |
2013-05-16 |
The Uab Research Foundation |
Her3 antibodies and uses thereof
|
|
CN108424456B
(zh)
|
2011-11-23 |
2022-04-26 |
医学免疫有限责任公司 |
特异于her3的结合分子及其用途
|
|
CN108341873B
(zh)
*
|
2011-12-05 |
2022-03-25 |
诺华股份有限公司 |
表皮生长因子受体3(her3)的抗体
|
|
EP2788381A2
(en)
*
|
2011-12-05 |
2014-10-15 |
Novartis AG |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
|
|
EP2788382A2
(en)
*
|
2011-12-05 |
2014-10-15 |
Novartis AG |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
|
US9975956B2
(en)
|
2011-12-22 |
2018-05-22 |
I2 Pharmaceuticals, Inc. |
Surrogate binding proteins which bind DR4 and/or DR5
|
|
AR089529A1
(es)
|
2011-12-30 |
2014-08-27 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
|
|
AU2013211939C1
(en)
|
2012-01-27 |
2018-06-07 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
CN104136464A
(zh)
*
|
2012-02-23 |
2014-11-05 |
U3制药有限公司 |
用于调节放射敏感性的her3抑制剂
|
|
WO2013148315A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
|
HRP20191690T1
(hr)
|
2012-04-27 |
2019-12-27 |
Millennium Pharmaceuticals, Inc. |
Molekule anti-gcc antitijela i njihova uporaba u ispitivanju osjetljivosti na gcc-ciljanu terapiju
|
|
HK1202431A1
(en)
*
|
2012-05-02 |
2015-10-02 |
Symphogen A/S |
Humanized pan-her antibody compositions
|
|
US20150239991A1
(en)
|
2012-09-25 |
2015-08-27 |
Glenmark Pharmaceuticals S.A. |
Purification of hetero-dimeric immunoglobulins
|
|
JP2015534997A
(ja)
*
|
2012-10-25 |
2015-12-07 |
ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
ＥｒｂＢ３と結合する抗原結合タンパク質
|
|
PE20151179A1
(es)
|
2012-11-01 |
2015-09-12 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
|
|
CN104755499B
(zh)
|
2012-11-08 |
2020-10-02 |
霍夫曼-拉罗奇有限公司 |
结合HER3 β-发夹和HER4 β-发夹的抗HER3/HER4抗原结合蛋白
|
|
CN104755500B
(zh)
|
2012-11-08 |
2020-10-02 |
霍夫曼-拉罗奇有限公司 |
结合HER3 β-发夹的HER3抗原结合蛋白
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
|
SG11201506451UA
(en)
|
2013-03-06 |
2015-09-29 |
Merrimack Pharmaceuticals Inc |
Anti-c-met tandem fc bispecific antibodies
|
|
EP2970494B1
(en)
*
|
2013-03-14 |
2017-12-13 |
The Board of Regents of The University of Texas System |
Her3 specific monoclonal antibodies for diagnostic and therapeutic use
|
|
WO2014152358A2
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
|
AU2014227732A1
(en)
|
2013-03-15 |
2015-09-17 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 beta and IL-17
|
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
|
EP2821071A1
(en)
|
2013-07-04 |
2015-01-07 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Compounds for breast cancer treatment
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
EP3712166A1
(en)
|
2013-09-05 |
2020-09-23 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
|
US11305012B2
(en)
|
2013-09-24 |
2022-04-19 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
|
WO2015066543A1
(en)
*
|
2013-11-01 |
2015-05-07 |
Board Of Regents, The University Of Texas System |
Targeting her2 and her3 with bispecific antibodies in cancerous cells
|
|
WO2015067986A1
(en)
|
2013-11-07 |
2015-05-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neuregulin allosteric anti-her3 antibody
|
|
WO2015100459A2
(en)
|
2013-12-27 |
2015-07-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
|
|
AU2015229591B2
(en)
|
2014-03-11 |
2020-10-22 |
Regeneron Pharmaceuticals, Inc. |
Anti-EGFRvlll antibodies and uses thereof
|
|
US12685781B2
(en)
|
2014-04-10 |
2026-07-21 |
Daiichi Sankyo Company, Limited |
Anti-HER3 antibody-drug conjugate
|
|
TWI871999B
(zh)
|
2014-04-10 |
2025-02-01 |
日商第一三共股份有限公司 |
抗her3抗體-藥物結合物
|
|
US10745490B2
(en)
|
2014-04-11 |
2020-08-18 |
Celldex Therapeutics, Inc. |
Anti-ErbB antibodies and methods of use thereof
|
|
FR3020063A1
(fr)
|
2014-04-16 |
2015-10-23 |
Gamamabs Pharma |
Anticorps humain anti-her4
|
|
KR20160144465A
(ko)
|
2014-05-14 |
2016-12-16 |
에프. 호프만-라 로슈 아게 |
Her3의 베타-헤어핀에 결합하는 항-her3 항체
|
|
WO2015175861A1
(en)
|
2014-05-16 |
2015-11-19 |
Amgen Inc. |
Assay for detecting th1 and th2 cell populations
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
CA2978631C
(en)
|
2015-03-09 |
2023-06-27 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to flt3 proteins
|
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
|
US10184006B2
(en)
|
2015-06-04 |
2019-01-22 |
Merrimack Pharmaceuticals, Inc. |
Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
CA2990572C
(en)
|
2015-06-29 |
2022-07-26 |
Daiichi Sankyo Company, Limited |
Method for selectively manufacturing antibody-drug conjugate
|
|
TW201716439A
(zh)
|
2015-07-20 |
2017-05-16 |
美國禮來大藥廠 |
Ｈｅｒ３抗體
|
|
US20220313841A1
(en)
*
|
2015-09-02 |
2022-10-06 |
Sanford Burnham Prebys Medical Discovery Institute |
Compositions and methods for treating nervous system injuries
|
|
MA43416A
(fr)
|
2015-12-11 |
2018-10-17 |
Regeneron Pharma |
Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
|
|
WO2017160990A1
(en)
|
2016-03-15 |
2017-09-21 |
Merrimack Pharmaceuticals, Inc. |
Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
|
|
IL261757B2
(en)
*
|
2016-03-18 |
2023-09-01 |
Univ Rutgers |
Treatment of stem cells with chemotherapeutic agents conjugated to anti-matriptase antibodies using connecting parts that can be broken down in the living body
|
|
EP3551667A4
(en)
|
2016-12-09 |
2020-06-17 |
Seattle Genetics, Inc. |
BIVALENT ANTIBODIES MASKED BY COILS
|
|
JPWO2018110515A1
(ja)
|
2016-12-12 |
2019-10-24 |
第一三共株式会社 |
抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
|
|
SG11201906554RA
(en)
|
2017-01-17 |
2019-08-27 |
Daiichi Sankyo Co Ltd |
Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
|
|
US12667557B2
(en)
|
2017-02-28 |
2026-06-30 |
Daiichi Sankyo Company, Limited |
Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate
|
|
AU2018235928B2
(en)
|
2017-03-14 |
2023-09-21 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
|
TWI926682B
(zh)
|
2017-05-15 |
2026-05-21 |
日商第一三共股份有限公司 |
抗體－藥物結合物之製造方法
|
|
KR20250004902A
(ko)
|
2017-08-23 |
2025-01-08 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 제제 및 그 동결 건조 방법
|
|
EP3677589B1
(en)
|
2017-08-31 |
2025-11-26 |
Daiichi Sankyo Company, Limited |
Improved method for producing antibody-drug conjugate
|
|
SG11202001514XA
(en)
|
2017-08-31 |
2020-03-30 |
Daiichi Sankyo Co Ltd |
Novel method for producing antibody-drug conjugate
|
|
EP3758751A4
(en)
|
2018-02-28 |
2021-11-17 |
Wuxi Biologics Ireland Limited. |
MONOCLONAL ANTIBODIES AGAINST HUMAN LAG-3, METHOD OF MANUFACTURING AND USING THEREOF
|
|
CN120463807A
(zh)
|
2018-03-22 |
2025-08-12 |
表面肿瘤学有限责任公司 |
抗il-27抗体及其用途
|
|
US12325737B2
(en)
|
2018-03-26 |
2025-06-10 |
Amgen Inc. |
Total afucosylated glycoforms of antibodies produced in cell culture
|
|
WO2019210144A1
(en)
*
|
2018-04-27 |
2019-10-31 |
Vanderbilt University |
Broadly neutralizing antibodies against hepatitis c virus
|
|
EP3794042B1
(en)
|
2018-05-18 |
2024-03-27 |
Daiichi Sankyo Co., Ltd. |
Anti-muc1- exatecan antibody-drug conjugate
|
|
SG11202100653YA
(en)
|
2018-07-25 |
2021-02-25 |
Daiichi Sankyo Co Ltd |
Effective method for manufacturing antibody-drug conjugate
|
|
EP3831853A4
(en)
|
2018-07-27 |
2022-06-01 |
Daiichi Sankyo Company, Limited |
ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT
|
|
IL325918A
(en)
|
2018-07-31 |
2026-03-01 |
Daiichi Sankyo Co Ltd |
Antibody-drug conjugates for use in the treatment of metastatic brain tumor
|
|
BR112021001750A2
(pt)
|
2018-08-06 |
2021-04-27 |
Daiichi Sankyo Company, Limited |
composição farmacêutica
|
|
CN112739826A
(zh)
|
2018-08-23 |
2021-04-30 |
第一三共株式会社 |
抗体-药物缀合物的敏感性标志物
|
|
CA3112043A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2020059772A1
(ja)
|
2018-09-20 |
2020-03-26 |
第一三共株式会社 |
抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
|
|
CN111289748A
(zh)
*
|
2018-12-08 |
2020-06-16 |
惠州市中大惠亚医院 |
ErbB3蛋白在制备膀胱癌无创诊断产品中的应用
|
|
AU2019396895B2
(en)
|
2018-12-11 |
2025-09-11 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate with PARP inhibitor
|
|
TW202039562A
(zh)
*
|
2018-12-12 |
2020-11-01 |
大陸商上海藥明生物技術有限公司 |
抗tim-3抗體及其用途
|
|
AU2019399474B2
(en)
*
|
2018-12-13 |
2026-07-30 |
Surface Oncology, LLC |
Anti-IL-27 antibodies and uses thereof
|
|
BR112021011894A2
(pt)
|
2018-12-21 |
2021-09-08 |
Daiichi Sankyo Company, Limited |
Composição farmacêutica
|
|
KR20220069982A
(ko)
|
2019-09-26 |
2022-05-27 |
암젠 인크 |
항체 조성물의 생산 방법
|
|
EP4045515A4
(en)
|
2019-10-18 |
2023-10-18 |
The Regents Of The University Of Michigan |
BIOMATERIAL SENSOR SYSTEMS
|
|
AU2020376934A1
(en)
|
2019-11-01 |
2022-06-02 |
Regeneron Pharmaceuticals, Inc. |
Anti-CD45 antibodies and conjugates thereof
|
|
MX2022008901A
(es)
*
|
2020-01-24 |
2022-08-16 |
Regeneron Pharma |
Conjugados de proteinas-compuestos antivirales.
|
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
|
US11896619B2
(en)
*
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
|
CN111282165B
(zh)
*
|
2020-03-18 |
2025-03-21 |
核工业总医院 |
放射治疗定位显影液及定位显影标记敷贴
|
|
WO2021247892A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
|
CN116133694B
(zh)
|
2020-10-14 |
2026-03-06 |
苏州盛迪亚生物医药有限公司 |
抗her3抗体和抗her3抗体药物偶联物及其医药用途
|
|
US20240043501A1
(en)
|
2020-10-15 |
2024-02-08 |
Amgen Inc. |
Relative unpaired glycans in antibody production methods
|
|
US20230414778A1
(en)
|
2020-11-11 |
2023-12-28 |
Daiichi Sankyo Company, Limited |
COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY
|
|
EP4247430A4
(en)
*
|
2020-11-20 |
2024-12-11 |
Actinium Pharmaceuticals, Inc. |
Her3 radioimmunotherapy for the treatment of solid cancers
|
|
US12551584B1
(en)
|
2020-12-07 |
2026-02-17 |
Actinium Pharmaceuticals, Inc. |
Lewis Y radioimmunotherapy for the treatment of cancer
|
|
US20240360436A1
(en)
|
2021-03-31 |
2024-10-31 |
DDBio. Co., Ltd. |
Vector and method for screening functional antigen-binding protein
|
|
US20240238440A1
(en)
|
2021-04-29 |
2024-07-18 |
Hyslink Therapeutics |
Preparation method for and application of antibody conjugated drug
|
|
AU2022289365A1
(en)
|
2021-06-07 |
2023-12-14 |
Amgen Inc. |
Using fucosidase to control afucosylation level of glycosylated proteins
|
|
EP4355787A4
(en)
*
|
2021-06-15 |
2025-04-30 |
Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. |
Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof
|
|
EP4393514A1
(en)
|
2021-08-24 |
2024-07-03 |
Kunshan Xinyunda Biotech Co., Ltd. |
Antibody-drug conjugate conjugated via breakable linker
|
|
JP2024537100A
(ja)
|
2021-10-05 |
2024-10-10 |
アムジエン・インコーポレーテツド |
Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
|
|
WO2023103854A1
(zh)
|
2021-12-09 |
2023-06-15 |
昆山新蕴达生物科技有限公司 |
一种亲和力改善的抗体-药物偶联物、其制备方法及应用
|
|
EP4470570A1
(en)
|
2022-01-28 |
2024-12-04 |
Duality Biologics (Suzhou) Co., Ltd. |
Her3 antibody-drug conjugate and use thereof
|
|
US20260028417A1
(en)
*
|
2022-03-03 |
2026-01-29 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Her3 binding protein and use thereof
|
|
CA3249707A1
(en)
|
2022-04-27 |
2023-11-02 |
Daiichi Sankyo Company, Limited |
COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH AN EZH1 AND/OR EZH2 INHIBITOR
|
|
WO2023208216A1
(en)
*
|
2022-04-29 |
2023-11-02 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Antibody-drug conjugates and preparation methods and use thereof
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
JP2025517656A
(ja)
|
2022-05-11 |
2025-06-10 |
第一三共株式会社 |
腫瘍抗原に特異的である抗体と、ｃｄ４７阻害剤との組合せ
|
|
KR20250145079A
(ko)
|
2023-02-09 |
2025-10-13 |
비원 메디슨즈 아이 게엠베하 |
자가 안정화 링커 접합체
|
|
JP2026516670A
(ja)
|
2023-04-20 |
2026-05-26 |
アムジエン・インコーポレーテツド |
相対的な不対グリカン含有量を決定する方法
|
|
JPWO2024248123A1
(enExample)
|
2023-06-02 |
2024-12-05 |
|
|
|
CN116444672B
(zh)
|
2023-06-13 |
2023-11-03 |
上海偌妥生物科技有限公司 |
人表皮生长因子3的抗体、其制备方法及其应用
|
|
CN121443323A
(zh)
|
2023-06-29 |
2026-01-30 |
广州百济神州生物制药有限公司 |
生物活性缀合物、其制备方法及用途
|
|
EP4735048A1
(en)
|
2023-06-29 |
2026-05-06 |
Beone Medicines I GmbH |
Bioactive conjugates, preparation method and use thereof
|
|
EP4737483A1
(en)
|
2023-06-30 |
2026-05-06 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate production method including purification step using activated carbon material
|
|
AU2024325342A1
(en)
|
2023-08-14 |
2026-02-26 |
Amgen Inc. |
Methods for reducing yellow color
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2025103474A1
(zh)
|
2023-11-17 |
2025-05-22 |
成都康弘生物科技有限公司 |
双毒素抗体药物偶联物及其用途
|
|
WO2025190404A1
(zh)
*
|
2024-03-14 |
2025-09-18 |
珠海普米斯生物科技有限公司 |
双特异性抗体、抗体药物偶联物及其应用
|
|
WO2026026529A1
(zh)
*
|
2024-07-29 |
2026-02-05 |
天劢源和生物医药（上海）有限公司 |
一种多特异性抗原结合蛋白及其应用
|
|
WO2026090253A1
(en)
|
2024-10-23 |
2026-04-30 |
Amgen Inc. |
Methods of determining glycan pairing content
|